Top

Current Neurology and Neuroscience Reports

Published in:

01-04-2015 | Headache (RB Halker, Section Editor)

Inpatient Management of Migraine

Authors: Michael J. Marmura, Stephanie Wrobel Goldberg

Published in: Current Neurology and Neuroscience Reports | Issue 4/2015

Abstract

Migraine is a frequently disabling disorder which may require inpatient treatment. Admission criteria for migraine include intractable migraine, nausea and/or vomiting, severe disability, and dependence on opioids or barbiturates. The inpatient treatment of migraine is based on observational studies and expert opinion rather than placebo-controlled trials. Well-established inpatient treatments for migraine include dihydroergotamine, neuroleptics/antiemetics, lidocaine, intravenous aspirin, and non-pharmacologic treatment such as cognitive–behavioral therapy. Short-acting treatments possibly associated with medication overuse, such as triptans, opioids, or barbiturate-containing compounds, are generally avoided. While the majority of persons with migraine are admitted on an emergency basis for only a few days, outcome studies and infusion protocols during elective admissions at tertiary headache centers suggest a longer length of stay may be needed for persons with intractable migraine.

Murray CJ, Lopez AD, Black R, et al. Global burden of disease 2005: call for collaborators. Lancet. 2007;370(9582):109–10.CrossRefPubMed

Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors. JAMA. 1992;26764–69.

Anonymous From the Centers for Disease Control. Prevalence of chronic migraine headaches—United States, 1980–1989. JAMA. 1991;265(22):2941.

Insinga RP, Ng-Mak DS, Hanson ME. Costs associated with outpatient, emergency room and inpatient care for migraine in the USA. Cephalalgia. 2011;31(15):1570–5.CrossRefPubMed

5.•

Lucado J, Paez K, Elixhauser A. Headaches in U.S. Hospitals and Emergency Departments, 2008: Statistical Brief #111. (2006) A relatively unusual look at actual costs of primary headache disorders as they are currently treated, using real-world data.

Lake AE, Saper JR, Madden SF, Kreeger C. Comprehensive inpatient treatment for intractable migraine: a prospective long-term outcome study. Headache. 1993;33:55–62.CrossRefPubMed

Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159813–818.

Vonkorff M, Stewart WF, Simon DS, Lipton RB. Migraine and reduced work performance: a population-based diary study. Neurology. 1998;501741–1745.

Osterhaus J, Gutterman DL, Pluchetka JR. Healthcare resource and lost labor costs of migraine headache in the United States. Pharmacol Econ. (1992) 267–76.

10.

Fishman P, Von KM, Lozano P, Hecht J. Chronic care costs in managed care. Health Aff (Millwood). 1997;16(3):239–47.CrossRef

11.

Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. Pain. 2009;142(3):179–82.CrossRefPubMed

12.

Ferrari A, Leone S, Tacchi R, et al. The link between pain patient and analgesic medication is greater in migraine than in rheumatic disease patients. Cephalalgia. 2009;29(1):31–7.CrossRefPubMed

13.••

Saper JR, Lake III AE. Continuous opioid therapy (COT) is rarely advisable for refractory chronic daily headache: limited efficacy, risks, and proposed guidelines. Headache. 2008;48(6):838–49. A guideline for management of daily headache, pointing out common pitfalls with opioid use seen in clinical practice.CrossRefPubMed

14.

Tribl GG, Schnider P, Wober C, et al. Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache? Cephalalgia. 2001;21(6):691–6.CrossRefPubMed

15.

Radat F, Sakh D, Lutz G, et al. Psychiatric comorbidity is related to headache induced by chronic substance use in migraineurs. Headache. 1999;39(7):477–80.CrossRefPubMed

16.

Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80(8):697–704.CrossRefPubMed

17.

Zeeberg P, Olesen J, Jensen R. Efficacy of multidisciplinary treatment in a tertiary referral headache centre. Cephalalgia. 2005;25(12):1159–67.CrossRefPubMed

18.•

Gaul C, Visscher CM, Bhola R, et al. Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache. J Headache Pain. 2011;12(5):511–9. An excellent overview of comprehensive headache management.CrossRefPubMedCentralPubMed

19.

Rizzoli P. Preventive pharmacotherapy in migraine. Headache. 2014;54(2):364–9.CrossRefPubMed

20.

Diener HC, Gaul C, Jensen R, et al. Integrated headache care. Cephalalgia. 2011;31(9):1039–47.CrossRefPubMed

21.••

Freitag FG, Lake A, Lipton RB, et al. Inpatient treatment of headache: an evidence-based assessment. United States Headache Guidelines Consortium. Headache. 2004;44:342–60. The most complete evidence and experience-based review of inpatient headache management to date.CrossRefPubMed

22.••

Dougherty CO, Marmura MJ, Ergonul Z, Charleston LC, Szperka CL. Emergency and inpatient treatment of migraine: an American Headache Society survey. Brit J Med Med Res. 2014;4(20):3800–13. A recent expert opinion paper on the topic of emergency and inpatient management.CrossRef

23.

Saper JR, Silberstein SD, Gordon CD, et al. Handbook of headache management. In: Saper JR, Silberstein SD, Gordon CD, Hamel RL, editors. Handbook of headache management. Baltimore: Williams & Wilkins; 1993.

24.

Solomon GD, Cady RK, Klapper JA, Ryan Jr RE. Standards of care for treating headache in primary care practice. National Headache Foundation. Cleve Clin J Med. 1997;64(7):373–83.CrossRefPubMed

25.

Villarreal SS. A comparative study of selected patient variables as risk factors in hospitalization for chronic headache. Headache. 1995;35:349–54.CrossRefPubMed

26.••

Lake III AE, Saper JR, Hamel RL. Comprehensive inpatient treatment of refractory chronic daily headache. Headache. 2009;49(4):555–62. A recent overview of chronic daily headache management with insight from the medical and psychological perspective.CrossRefPubMed

27.

Diamond S, Freitag FG, Maliszewski M. Inpatient treatment of headache: long-term results. Headache. 1986;26:189–97.CrossRefPubMed

28.

Linder SL. Treatment of acute childhood migraine headaches. Cephalalgia. 1991;11 Suppl 11:120–1.

29.

Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36995–997.

30.

Silberstein SD, Silberstein JR. Chronic daily headache: prognosis following inpatient treatment with repetitive IV DHE. Headache. 1992;32439–445.

31.

Pringsheim T, Howse D. Inpatient treatment of chronic daily headache using dihydroergotamine: a long-term follow-up study. Can J Neurol Sci. 1998;25146–150.

32.•

Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827–32. One of a few recent large inpatient studies of DHE.CrossRefPubMed

33.

Jauslin P, Goadsby PJ, Lance JW. The hospital management of severe migrainous headache. Headache. 1991;31658–660.

34.

Relja G, Granato A, Bratina A, Antonello RM, Zorzon M. Outcome of medication overuse headache after abrupt in-patient withdrawal. Cephalalgia. 2006;26(5):589–95.CrossRefPubMed

35.

Diener HC. The efficacy and safety of acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized multicenter, parallel group study. The ASASUMAMIG Study Group. Eur Neurol. (1999).

36.

Lipton RB, Goldstein J, Baggish JS, et al. Aspirin is efficacious for the treatment of acute migraine. Headache. 2005;45(4):283–92.CrossRefPubMed

37.•

Weatherall MW, Telzerow AJ, Cittadini E, Kaube H, Goadsby PJ. Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache. Neurology. 2010;75(12):1098–103. A novel inpatient approach to daily headache in the hospital setting.CrossRefPubMed

38.

Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache. 2002;42(6):519–22.CrossRefPubMed

39.

Stillman MJ, Zajac D, Rybicki LA. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. Headache. 2004;44(1):65–9.CrossRefPubMed

40.

Mathew NT, Kailasam J, Meadors L, Gentry P, Chernyshev O. Intravenous valproate sodium (Depaconr) aborts migraine rapidly: a preliminary report. Cephalalgia. 1999;19:373. Abstract.CrossRef

41.

Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache. 2001;41(10):976–80.CrossRefPubMed

42.

Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia. 2003;23(10):963–71.CrossRefPubMed

43.•

Rosen N, Marmura M, Abbas M, Silberstein S. Intravenous lidocaine in the treatment of refractory headache: a retrospective case series. Headache. 2009;49(2):286–91. A large review of lidocaine for chronic migraine and other headaches in the inpatient setting, with or without adjunctive medication.CrossRefPubMed

44.

Marmura MJ, Passero Jr FC, Young WB. Mexiletine for refractory chronic daily headache: a report of nine cases. Headache. 2008;48(10):1506–10.CrossRefPubMed

45.

Gil-Gouveia R, Goadsby PJ. Neuropsychiatric side effects of lidocaine: examples from the treatment of headache and a review. Cephalalgia. 2006;26:1399. Abstract.

46.

Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002;22(5):345–53.CrossRefPubMed

47.

Demirkaya S, Vural O, DORA B, Topcuoglu MA. Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache. 2001;41(2):171–7.CrossRefPubMed

48.

Frank LR, Olson CM, Shuler KB, Gharib SF. Intravenous magnesium for acute benign headache in the emergency department: a randomized double-blind placebo-controlled trial. CJEM. 2004;6(5):327–32.PubMed

49.

Choi H, Parmar N. The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials. Eur J Emerg Med. 2014;21(1):2–9.PubMed

50.

Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia. 2005;25(3):199–204.CrossRefPubMed

51.

Ginder S, Oatman B, Pollack M. A prospective study of i.v. magnesium and i.v. prochlorperazine in the treatment of headaches. J Emerg Med. 2000;18(3):311–5.CrossRefPubMed

52.

Somerville BW. Treatment of migraine attacks with an analgesic combination (Mersyndol). Med J Aust. 1976;1(23):865–6.PubMed

53.

Swidan SZ, Lake III AE, Saper JR. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache. Curr Pain Headache Rep. 2005;9(1):65–70.CrossRefPubMed

54.

Orr sl, Aube M, Becker WJ, et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia (2014).

55.

Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med. 2010;56(1):1–6.CrossRefPubMed

56.

Jones EB, Gonzales ER, Boggs JG, Grillo JA, Elswick JR RK. Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994;24237–241.

57.

Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA. 1989;261(8):1174–6.CrossRefPubMed

58.

Wang SJ, Silberstein SD, Young WB. Droperidol treatment of status migrainosus and refractory migraine. Headache. 1997;37377–382.

59.

Silberstein SD, Young WB, Mendizabal JE, Rothrock JF, Alam AS. Acute migraine treatment with droperidol: a randomized, double-blind, placebo-controlled trial. Neurology. 2003;60(2):315–21.CrossRefPubMed

60.

Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002;23(2):141–8.CrossRefPubMed

61.

Lane PL, Mclellan BA, Boggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med. 1989;18360–365.

62.

Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache. 2006;46(5):781–7.CrossRefPubMed

63.

Klapper JA, Stanton JS. Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. Headache. 1991;31523–524.

64.

Tfelt-Hansen P, Olesen J, Aebelholt-Krabbe A, Melgaard B, Veilis B. A double blind study of metoclopramide in the treatment of migraine attacks. J Neurol Neurosurg Psychiatry. 1980;43369–371.

65.

Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache. 2000;40(3):224–30.CrossRefPubMed

66.

Mosier J, Roper G, Hays D, Guisto J. Sedative dosing of propofol for treatment of migraine headache in the emergency department: a case series. West J Emerg Med. 2013;14(6):646–9.CrossRefPubMedCentralPubMed

67.

Soleimanpour H, Taheraghdam A, Ghafouri RR, et al. Improvement of refractory migraine headache by propofol: case series. Int J Emerg Med. 2012;5(1):19.CrossRefPubMedCentralPubMed

68.•

Mendes PM, Silberstein SD, Young WB, Rozen TD, Paolone MF. Intravenous propofol in the treatment of refractory headache. Headache: J Head Face Pain. 2002;42(7):638–41. One of the largest studies looking at propofol for the treatment of intractable pain.CrossRef

69.

Nelson DS, Walsh K, Fleisher GR. Spectrum and frequency of pediatric illness presenting to a general community hospital emergency department. Pediatrics. 1992;90(1 Pt 1):5–10.PubMed

70.

Kandt RS, Levine RM. Headache and acute illness in children. J Child Neurol. 1987;2(1):22–7.CrossRefPubMed

71.

Lewis DW, Qureshi F. Acute headache in children and adolescents presenting to the emergency department. Headache. 2000;40(3):200–3.CrossRefPubMed

72.•

Kabbouche MA, Powers SW, Segers A, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache. 2009;49(1):106–9. One of only a few pediatric studies focusing on the treatment of chronic migraine.CrossRefPubMed

73.

Kabbouche MA, Vockell AL, Lecates SL, Powers SW, Hershey AD. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics. 2001;107(4):E62.CrossRefPubMed

74.

Raina M, Chelimsky G, Chelimsky T. Intravenous dihydroergotamine therapy for pediatric abdominal migraines. Clin Pediatr (Phila). 2013;52(10):918–21.CrossRef

75.

Lake A, Saper J, Madden S, Kreeger C. Inpatient treatment for chronic daily headache: a prospective long-term outcome. Headache. 1990;30:299–300. Abstract.

76.

Lanzi G, D’Arrigo S, Termine C, et al. The effectiveness of hospitalization in the treatment of paediatric idiopathic headache patients. Psychopathology. 2007;40(1):1–7.CrossRefPubMed

77.

Hechler T, Dobe M, Kosfelder J, et al. Effectiveness of a 3-week multimodal inpatient pain treatment for adolescents suffering from chronic pain: statistical and clinical significance. Clin J Pain. 2009;25(2):156–66.CrossRefPubMed

78.

Wall M, Kupersmith MJ, Kieburtz KD, et al. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol. 2014;71(6):693–701.CrossRefPubMed

79.

Silberstein SD. Practice parameter–evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology for the United States Headache Consortium. Neurology. 2000;55754–762.

80.

Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;521456–1470.

81.

Tietjen GE, Brandes JL, Peterlin BL, et al. Childhood maltreatment and migraine (part II). Emotional abuse as a risk factor for headache chronification. Headache. 2010;50(1):32–41.CrossRefPubMed

82.

Peterlin BL, Rosso AL, Rapoport AM, Scher AI. Obesity and migraine: the effect of age, gender and adipose tissue distribution. Headache. 2010;50(1):52–62.CrossRefPubMedCentralPubMed

83.

Bond DS, Vithiananthan S, Nash JM, Thomas JG, Wing RR. Improvement of migraine headaches in severely obese patients after bariatric surgery. Neurology. 2011;76(13):1135–8.CrossRefPubMedCentralPubMed

84.

Lipton RB, Stewart WF, Sawyer J. Stratified care is a more effective migraine treatment strategy than stepped care: results of a randomized clinical trial. Neurology. (2000) 54A14.

Title: Inpatient Management of Migraine
Authors: Michael J. Marmura
Stephanie Wrobel Goldberg
Publication date: 01-04-2015
Publisher: Springer US
Published in: Current Neurology and Neuroscience Reports / Issue 4/2015
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-015-0539-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Inpatient Management of Migraine

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

Neurogenic Changes in the Upper Airway of Obstructive Sleep Apnoea

Concussion and Football: a Review and Editorial

Behavioral Treatments for Migraine Management: Useful at Each Step of Migraine Care

Dietary Interventions to Lower the Risk of Stroke

The Relationship Between Herpes Zoster and Stroke

The Role of Neuroinflammation in Dementias